Quest PharmaTech Inc. (TSX-V: QPT)
("Quest" or the "Company"), a pharmaceutical company developing and
commercializing products for the treatment of cancer, announces that it
has received clearance from the United States Food and Drug
Administration to initiate U.S. sites for an ongoing international
Phase II clinical trial for oregovomab in advanced ovarian cancer
patients. The objective of this study is to evaluate whether optimally
dosed oregovomab in conjunction with front-line chemotherapy will
generate the same or an improved immune and clinical response, as seen
in a previous Phase II clinical trial in a similar ovarian cancer
patient population.
The U.S. centers include Michiana Hematology and Oncology at South Bend,
Indiana with Dr. Michael Method as the lead investigator; University of Connecticut Health Center at Farmington, Connecticut with
Dr. Molly R. Brewer as the lead investigator, and the Stanford Cancer
Institute at Stanford, California with Dr. Jonathan S. Berek as the
lead investigator.
Two of the three participating U.S. centers have received all necessary
regulatory approvals and are now actively recruiting patients. The
third center is awaiting IRB approval. Additional information on the
Company's clinical trial can be found listed in www.ClinicalTrials.gov.